With 0.65 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.83 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $20.385 whereas the lowest price it dropped to was $19.945. The 52-week range on BLCO shows that it touched its highest point at $21.69 and its lowest point at $13.16 during that stretch. It currently has a 1-year price target of $20.83. Beta for the stock currently stands at 0.48.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BLCO was down-trending over the past week, with a drop of -3.32%, but this was up by 4.53% over a month. Three-month performance surged to 29.30% while six-month performance rose 34.77%. The stock gained 22.81% in the past year, while it has gained 17.70% so far this year. A look at the trailing 12-month EPS for BLCO yields -1.30 with Next year EPS estimates of 0.85. For the next quarter, that number is 0.16. This implies an EPS growth rate of -17.37% for this year and 41.32% for next year.
Float and Shares Shorts:
At present, 350.91 million BLCO shares are outstanding with a float of 38.79 million shares on hand for trading. On 2024-09-30, short shares totaled 1.44 million, which was 41.0 higher than short shares on 1724976000. In addition to Mr. Brenton L. Saunders J.D. as the firm’s CEO & Chairman, Mr. Osama A. Eldessouky serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.11743 of BLCO’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, BLCO reported revenue of $1216000000.0 and operating income of $40000000.0. The EBITDA in the recently reported quarter was $150000000.0 and diluted EPS was -$0.43.
